JP6808728B2 - 脳脊髄液の検出 - Google Patents
脳脊髄液の検出 Download PDFInfo
- Publication number
- JP6808728B2 JP6808728B2 JP2018517676A JP2018517676A JP6808728B2 JP 6808728 B2 JP6808728 B2 JP 6808728B2 JP 2018517676 A JP2018517676 A JP 2018517676A JP 2018517676 A JP2018517676 A JP 2018517676A JP 6808728 B2 JP6808728 B2 JP 6808728B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- transferrin
- stf
- hydrazide
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001175 cerebrospinal fluid Anatomy 0.000 title claims description 69
- 238000001514 detection method Methods 0.000 title claims description 23
- 239000012581 transferrin Substances 0.000 claims description 136
- 102000004338 Transferrin Human genes 0.000 claims description 105
- 108090000901 Transferrin Proteins 0.000 claims description 105
- 239000000523 sample Substances 0.000 claims description 70
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 29
- 239000012472 biological sample Substances 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 25
- 239000007800 oxidant agent Substances 0.000 claims description 16
- 125000005629 sialic acid group Chemical group 0.000 claims description 15
- 125000003172 aldehyde group Chemical group 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108010015133 Galactose oxidase Proteins 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 46
- 238000007254 oxidation reaction Methods 0.000 description 22
- 230000003647 oxidation Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 13
- 206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 102000005348 Neuraminidase Human genes 0.000 description 9
- 108010006232 Neuraminidase Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000006148 magnetic separator Substances 0.000 description 7
- 230000000737 periodic effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 239000002923 metal particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 206010040102 Seroma Diseases 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000012125 lateral flow test Methods 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010057751 Post procedural discharge Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- -1 periodate (eg Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/32—Post-translational modifications [PTMs] in chemical analysis of biological material biotinylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
本出願は、2015年6月18日付出願の米国仮特許出願第62/181469号(その内容は全て引用することにより本明細書の一部をなす)の利益を主張する。
a.生体試料を得る工程と、
b.末端残基中にアルデヒド基を含む酸化シアロ−トランスフェリン(sTF)を生成するのに十分な量の酸化剤を試料に添加する工程と、
c.工程bから得られる試料と、ヒドラジド反応性基を含む試薬とを接触させる工程であって、酸化sTFが該ヒドラジド反応性基に結合して複合体を形成する、工程と、
d.試料から複合体を除去して残留試料を形成する工程と、
e.残留試料中の残留トランスフェリンの存在を検出する工程と、
を含み、
生体試料中の残留トランスフェリンの検出がCSFの存在を示す、方法に関する。
a.生体試料を得ることと、
b.末端残基中にアルデヒド基を含む酸化sTFを生成するのに十分な量の酸化剤を試料に添加することと、
c.工程bから得られる試料と、ヒドラジド反応性基を含む試薬とを接触させることであって、酸化sTFが反応性基に結合して複合体を形成することと、
d.試料から複合体を除去することと、
を含む、方法に関する。
a.手術に先立って被験体から第1の生体試料を得るとともに、該第1の試料中に存在するトランスフェリンを測定することと、
b.手術中又は手術後に被験体から第2の生体試料を得るとともに、該第2の試料中に存在するトランスフェリンを測定することと、
を含み、
第1の試料中に存在するトランスフェリンと比較して第2の試料中に存在するより多量のトランスフェリンがCSF漏れを示す、方法を包含する。
a.試料ローディング領域と、
b.試料ローディング領域の下流の濾過領域であって、sTFに結合する固定化試薬を含む、濾過領域と、
c.抗トランスフェリン抗体を含む濾過領域の下流の結合領域と、
を備える、試料中のトランスフェリンを検出する又は測定するための試験片に関する。
2.1 酵素反応及び標識化
ヒト血清sTF(10mg/mL(Sigma))を、1×Glycobuffer(5mM CaCl2を含むpH5.5の20mM酢酸ナトリウムバッファー)に溶解した。ヒトsTF溶液を37℃で一晩ノイラミニダーゼ(1×Glycobuffer(Sigma)中1mg/mL)で処理してaTFを生成した。sTF及びaTFの両方を製造業者のプロトコルに従ってNHS−ローダミン(Pierce)で標識化した。全ての未反応ローダミンをPD MiniTrap G−25カラム(GE Heathcare)上のカラムクロマトグラフィによって除去した。
40mLの1×Tris−ホウ酸塩バッファー(89mM Trisベース及び89mMホウ酸、pH8.0)中に0.4gのアガロース粉末(Sigma)を溶解した後、電子レンジでアガロースを溶かすことによってアガロースゲル(1%)を調製し、その後、溶けたアガロース溶液を成形トレイに注ぎ、室温に冷却することで固体ゲルを形成した。ローディング試料を、ローダミン標識化タンパク質(10μL中20ng〜320ng)を30%グリセロール(2μL)と混合することにより調製した。タンパク質試料をロードした後、ゲルを200Vで15分間電気泳動に供した。
4℃(氷上)で30分間にわたり1mM NaIO4を用いて穏やかな過ヨウ素酸酸化を行い、TF中で非還元末端シアル酸残基を酸化した。過ヨウ素酸酸化中に生成された過剰な過ヨウ素酸塩及びホルムアルデヒドをPD Mini Trap G−25カラム(GE Heathcare)によって除去した。G−25カラムを使用する脱塩及びpH7.0のリン酸ナトリウムバッファー100mMによるバッファー交換の後、酸化シアル酸残基を含むTFをSiMAG−ヒドラジドミクロ粒子(Chemicell)で捕捉した。
SiMAG−ヒドラジド粒子(10mg/ml)をpH7.0、100mMのリン酸ナトリウムバッファーで2回洗浄した後、該粒子を、酸化シアル酸残基を含むTFとともに20℃で3時間インキュベートした。タンパク質−粒子抱合体を、磁気分離器を使用してペレット化した。上清中に残ったタンパク質をAmicon超遠心分離フィルタ(Ultracel−3K)によって回収し濃縮した。aTFを含む濃縮試料をアガロースゲル電気泳動によるか、又はトランスフェリンELISAキット(Abcam)を使用して分析した。
トランスフェリンELISAアッセイキット(Abcam)で試験試料中のヒトTFを検出することができた。簡潔には、標準試料又は試験試料をTF特異抗体で予め被覆した96ウェルプレートに添加した後、特異的ビオチン化TF検出抗体を添加し、該プレートを洗浄バッファーで洗浄した。ストレプトアビジン−ペルオキシダーゼ複合体を添加し、結合していない抱合体を洗浄バッファーで洗い流した。TMBがペルオキシダーゼによって触媒され、酸性停止溶液を添加した後に黄変する青色生成物を生成することで、TMBを使用してストレプトアビジン−ペルオキシダーゼ酵素反応を可視化した。450nmの波長においてマイクロプレートリーダー(SpectraMax M5(Molecular Devices))で黄色の吸光度を直ちに測定した。詳細なELISAプロトコルは、製造業者のガイドライン(Abcam)に従った。
ノイラミニダーゼを使用してsTFからaTFを生成した。シアル酸残基の除去後、TFをNHS−ローダミンを使用して標識化した(図2A)。アガロースゲル電気泳動を使用して、ローダミン標識化aTF及びsTFを分離することができた(図2B)。結果は、より多くの負に帯電したsTFが陽極近くに移動したことを示した。さらに、ヒト血漿中においてローダミン標識化トランスフェリンを選択的に検出することができた(図2B)。ローダミン標識化TFに対する検出限界は2μg/mLであり(図2C)、それは免疫固定(IFE)ゲル電気泳動による検出に類似する[19]。
[1] Barrios, C, Ahmed, M., Arrotegui, J. I., Bjornsson, A., J Spinal Disorders 1990, 3, 205-209.
[2] Cammisa, F. P., Jr., Girardi, F. P., Sangani, P. K., Parvataneni, H. K., Cadag, S., Sandhu, H. S., Spine 2000, 25, 2663-2667.
[3] Khan, M. H., Rihn, J., Steele, G., Davis, R, Donaldson, W. F., 3rd, Kang, J. D., Lee, J. Y., Spine 2006, 31, 2609-2613.
[4] Stolke, D., Sollmann, W. P., Seifert, V., Spine 1989, 14, 56-59.
[5] Wang, J. C, Bohlman, H. H., Riew, K. D., J Bone Joint Surgery (Am) 1998, 80, 1728-1732.
[6] Eismont, F. J., Wiesel, S. W., Rothman, R. H., J Bone Joint Surgery (Am) 1981, 63, 1132-1136.
[7] Brown, K. J., Vanderver, A., Hoffman, E. P., Schiffmann, R., Hathout, Y., Int JMass Spectrom 2012, 312, 97-106.
[8] Jou, Y. J., Lin, C. D., Lai, C. H., Chen, C. H., Kao, J. Y., Chen, S. Y., Tsai, M. H., Huang, S. H., Lin, C. W., Anal Chim Acta 2010, 681, 41-48.
[9] Whitfield, J. B., Clin Chem 2002, 48, 2095-2096.
[10] Wang, C, Li, C, Gong, W., Lou, T., BiomarkRes 2013, 1, 9.
[11] Coddeville, B., Carchon, H., Jaeken, J., Briand, G, Spik, G, Glycoconj J 1998, 15, 265-273.
[12] de Jong, G, van Noort, W. L., van Eijk, H. G, Electrophoresis 1992, 13, 225-228.
[13] Kallee, E., Lohss, F., Debiasi, S., NuclMed 1963, 2, Suppl 1 : 111-118.
[14] Iourin, O., Mattu, T. S., Mian, N., Keir, G, Winchester, B., Dwek, R. A., Rudd, P. M., Glycoconj J 1 1996, 13, 1031-1042.
[15] Nandapalan, V., Watson, I. D., Swift, A. C, Clinical otolaryngology and allied sciences 1996, 21, 259-264.
[16] Arrer, E., Meco, C, Oberascher, G, Piotrowski, W., Albegger, K., Patsch, W., Clin Chem 2002, 48, 939-941.
[17] Vanderver, A., Schiffmann, R., Timmons, M., Kellersberger, K. A., Fabris, D., Hoffman, E. P., Maletkovic, J., Hathout, Y., Clin Chem 2005, 51, 2031-2042.
[18] Roelandse, F. W., van der Zwart, N., Didden, J. H., van Loon, J., Souverijn, J. H., Clin Chem 1998, 44, 351-353.
[19] Normansell, D. E., Stacy, E. K., Booker, C. F., Butler, T. Z., Clin Otolaryngol Allied Sci 1994, 1, 68-70.
[20] Gorogh, T., Rudolph, P., Meyer, J. E., Werner, J. A., Lippert, B. M., Maune, S., Clin Chem 2005, 51, 1704-1710.
[21] Legros, F. J., Nuyens, V., Baudoux, M., Zouaoui Boudj eltia, K., Ruelle, J. L., Colicis, J., Cantraine, F., Henry, J. P., Clin Chem 2003, 49, 440-449.
[22] Zeng, Y., Ramya, T. N., Dirksen, A., Dawson, P. E., Paulson, J. C, Nat Methods 2009, 6, 207-209.
[23] De Bank, P. A., Kellam, B., Kendall, D. A., Shakesheff, K. M., Biotechnol Bioeng 2003, 81, 800-808.
[24] Choi, D., Spann, R., Br JNeurosurg 1996, 10, 571-575.
[25] Gallo, P., Bracco, F., Morara, S., Battistin, L., Tavolato, B., J Neurol Sci 1985, 70, 81-92.
Claims (5)
- a.試料ローディング領域と、
b.前記試料ローディング領域の下流の濾過領域であって、酸化シアロ−トランスフェリン(sTF)に結合するヒドラジド反応性基を含む固定化試薬を含み、該酸化sTFはその末端シアル酸残基中にアルデヒド基を含む、濾過領域と、
c.抗トランスフェリン抗体を含む前記濾過領域の下流の結合領域と、
d.前記結合領域の下流の捕捉領域であって、抗トランスフェリン抗体−トランスフェリン複合体に結合する固定化抗トランスフェリン抗体を含む、捕捉領域と、
を備える、試料中のアシアロ−トランスフェリンを検出する又は測定するための試験片。 - 前記ヒドラジド反応性基を含む固定化試薬が、ヒドラジド基で官能基化された高分子である、請求項1に記載の試験片。
- 前記固定化試薬がヒドラジド粒子を含む、請求項1に記載の試験片。
- 試料中のアシアロ−トランスフェリンの存在を検出するためのキットであって、
a.請求項1に記載の試験片と、
b.前記試験片を含むハウジングであって、試料ローディング域において前記試験片の表面を前記試料に曝露させるための少なくとも1つの開口を備える、ハウジングと、
c.過ヨウ素酸塩である化学酸化剤又はガラクトースオキシダーゼである酵素酸化剤を含む容器と、
を備える、キット。 - 生体試料中の脳脊髄液(CSF)の存在を検出する方法であって、
a.末端残基中にアルデヒド基を含む酸化シアロ−トランスフェリン(sTF)を生成するのに十分な量の過ヨウ素酸塩である化学酸化剤又はガラクトースオキシダーゼである酵素酸化剤を該試料に添加する工程と、
b.工程aから得られる試料と、ヒドラジド反応性基を含む試薬とを接触させる工程であって、前記酸化sTFが該ヒドラジド反応性基に結合して複合体を形成する、工程と、
c.前記試料から前記複合体を除去して残留試料を形成する工程と、
d.前記残留試料中のトランスフェリンの存在を検出する工程と、
を含み、
前記工程dのトランスフェリンの検出が前記試料中のCSFの存在を示す、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562181469P | 2015-06-18 | 2015-06-18 | |
US62/181,469 | 2015-06-18 | ||
PCT/US2016/038062 WO2016205637A2 (en) | 2015-06-18 | 2016-06-17 | Detection of cerebrospinal fluid |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018524611A JP2018524611A (ja) | 2018-08-30 |
JP2018524611A5 JP2018524611A5 (ja) | 2019-07-04 |
JP6808728B2 true JP6808728B2 (ja) | 2021-01-06 |
Family
ID=57546321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517676A Active JP6808728B2 (ja) | 2015-06-18 | 2016-06-17 | 脳脊髄液の検出 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11067581B2 (ja) |
EP (1) | EP3311142B1 (ja) |
JP (1) | JP6808728B2 (ja) |
KR (1) | KR20180023955A (ja) |
CN (1) | CN107850548A (ja) |
CA (1) | CA2988542C (ja) |
HK (1) | HK1254628A1 (ja) |
WO (1) | WO2016205637A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180052122A (ko) | 2015-09-04 | 2018-05-17 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 임상용 분석물 수집, 추출, 농축 및 검출을 위한 방법 및 장치 |
WO2018183211A1 (en) * | 2017-03-27 | 2018-10-04 | The Regents Of The University Of California | Semi-quantitative lateral-flow immunoassay for the detection of csf leaks |
US20220091118A1 (en) * | 2019-01-31 | 2022-03-24 | Nspc Technologies, Llc | Detection of cerebrospinal fluid |
AU2020376805A1 (en) * | 2019-10-30 | 2022-06-16 | Sanguis Diagnostics Corp. | Lateral flow assay systems and methods for the quantification of a biological sample |
CN111257568A (zh) * | 2020-02-24 | 2020-06-09 | 中国科学院昆明动物研究所 | 检测转铁蛋白表达量的试剂在制备肠道免疫耐受失衡疾病诊断试剂或试剂盒中的应用 |
WO2022107876A1 (ja) * | 2020-11-20 | 2022-05-27 | 株式会社堀場製作所 | 捕捉用デバイス |
CN113655035A (zh) * | 2021-08-12 | 2021-11-16 | 深圳上泰生物工程有限公司 | 一种糖缺失性转铁蛋白分离方法及检测方法与试剂盒 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01165960A (ja) * | 1987-12-23 | 1989-06-29 | Tosoh Corp | トランスフェリンの測定方法 |
SE9801563D0 (sv) * | 1998-04-30 | 1998-04-30 | Pharmacia & Upjohn Diag Ab | Förfarande med separation och kit att användas vid förfarandet |
GB9827411D0 (en) * | 1998-12-11 | 1999-02-03 | Axis Biochemicals Asa | Dipstick assay |
EP1514107B1 (en) * | 2002-06-03 | 2013-05-15 | The Institute for Systems Biology | Methods for quantitative proteome analysis of glycoproteins |
US20040002168A1 (en) * | 2002-06-13 | 2004-01-01 | Neuropro Technologies, Inc. | Apparatus and methods for detecting cerebrospinal fluid |
BRPI0711388B1 (pt) * | 2006-05-09 | 2021-02-23 | Beckman Coulter, Inc | método para detectar um analito em uma amostra em um procedimento de ensaio |
US20090208975A1 (en) * | 2007-12-13 | 2009-08-20 | Beckman Coulter, Inc. | Device and methods for detecting a target cell |
US20120288959A1 (en) * | 2009-06-08 | 2012-11-15 | Acrotech Systems Inc. | Rapid detection of cerebrospinal fluid, methods and systems therefore |
US20140135235A1 (en) * | 2011-06-06 | 2014-05-15 | Hui Zhang | Glycan and glycopeptide capture and release using reversible hydrazone-based method |
-
2016
- 2016-06-17 KR KR1020187001245A patent/KR20180023955A/ko not_active Application Discontinuation
- 2016-06-17 EP EP16812516.9A patent/EP3311142B1/en active Active
- 2016-06-17 US US15/737,352 patent/US11067581B2/en active Active
- 2016-06-17 CN CN201680035413.0A patent/CN107850548A/zh active Pending
- 2016-06-17 JP JP2018517676A patent/JP6808728B2/ja active Active
- 2016-06-17 WO PCT/US2016/038062 patent/WO2016205637A2/en active Application Filing
- 2016-06-17 CA CA2988542A patent/CA2988542C/en active Active
-
2018
- 2018-10-24 HK HK18113595.2A patent/HK1254628A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018524611A (ja) | 2018-08-30 |
US20190004057A1 (en) | 2019-01-03 |
WO2016205637A2 (en) | 2016-12-22 |
WO2016205637A3 (en) | 2017-01-26 |
CA2988542A1 (en) | 2016-12-22 |
CN107850548A (zh) | 2018-03-27 |
EP3311142A4 (en) | 2018-12-12 |
EP3311142B1 (en) | 2020-09-16 |
EP3311142A2 (en) | 2018-04-25 |
US11067581B2 (en) | 2021-07-20 |
KR20180023955A (ko) | 2018-03-07 |
CA2988542C (en) | 2023-10-17 |
HK1254628A1 (zh) | 2019-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6808728B2 (ja) | 脳脊髄液の検出 | |
JP6441407B2 (ja) | 非特異的結合を減少させるためのイムノアッセイ方法及び試薬 | |
US9599609B2 (en) | Lateral flow strip assay with immobilized conjugate | |
US20050176078A1 (en) | Detection and/or monitoring of synuclein-related diseases | |
US20200209238A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
US20210364515A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
KR20160120675A (ko) | 래피드 정량 진단 키트 | |
JP6074846B2 (ja) | 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー | |
US8460884B2 (en) | Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease | |
US20220091118A1 (en) | Detection of cerebrospinal fluid | |
JP5453443B2 (ja) | 精巣抗原に対する自己抗体検出のための免疫検査 | |
WO2021070934A1 (ja) | がんの検査方法 | |
JPH05507095A (ja) | 子宮内膜抗原、組成物、試験キット及び子宮内膜抗体検出方法 | |
JP6829689B2 (ja) | 免疫試験方法および免疫試験キット | |
WO2021010462A1 (ja) | ベーチェット病の診断を補助する方法及び検査用キット | |
US20160169884A1 (en) | Device and method for biological analyses | |
JPH0322945B2 (ja) | ||
JP2007024661A (ja) | 糖鎖不全IgA分子の定量方法及び定量キット | |
JP2006284330A (ja) | アシアロgm1の免疫学的測定キット並びに抗アシアロgm1抗体の免疫学的測定キット | |
JPH06289021A (ja) | 遊離型セクレタリー・コンポーネントの定量法及び測定キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20181210 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20181210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190528 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190528 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6808728 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |